News
Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights
- Favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year for once daily brilaroxazine in open-label extension (OLE) trial - - Registrational Phase 3 RECOVER-2 trial initiation for brilaroxazine expected mid-2025 - - Full data set from...
Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress
CUPERTINO, Calif., March 30, 2025 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic...
Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
CUPERTINO, Calif., Feb. 04, 2025 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Reviva to Participate in the 2025 BIO CEO & Investor Conference
CUPERTINO, Calif., Jan. 30, 2025 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit
CUPERTINO, Calif., Jan. 07, 2025 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants
CUPERTINO, Calif., Dec. 16, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Reviva Announces Proposed Public Offering
CUPERTINO, Calif., Dec. 16, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia
- Once daily brilaroxazine demonstrated favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year - - Generally well-tolerated with low rates of adverse events and discontinuation - - Full data set from open-label extension (OLE) of RECOVER...
Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia
- Once daily brilaroxazine demonstrated favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year - - Generally well-tolerated with low rates of adverse events and discontinuation - - Full data set from open-label extension (OLE) of RECOVER...
Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights
- 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial - - Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine's improvement on negative symptoms and other key symptom domains of schizophrenia - -...